Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.51 and traded as low as $3.45. Cryo-Cell International shares last traded at $3.56, with a volume of 1,803 shares changing hands.

Cryo-Cell International Price Performance

The stock has a 50-day moving average price of $3.55 and a two-hundred day moving average price of $3.51. The stock has a market cap of $28.69 million, a PE ratio of -10.79 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its earnings results on Tuesday, April 14th. The company reported $0.01 EPS for the quarter. The firm had revenue of $7.68 million during the quarter.

Institutional Trading of Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.